


## Bimatoprost-d<sub>5</sub>

<b>Cat. No.:</b>	HY-B0191S		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>32</sub> D <sub>5</sub> NO <sub>4</sub>		
<b>Molecular Weight:</b>	420.6		
<b>Target:</b>	Prostaglandin Receptor		
<b>Pathway:</b>	GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (237.76 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mM	2.3776 mL	11.8878 mL
5 mM			0.4755 mL	2.3776 mL	4.7551 mL
10 mM			0.2378 mL	1.1888 mL	2.3776 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Bimatoprost-d<sub>5</sub> is a deuterium labeled Bimatoprost. Bimatoprost is a prostaglandin analog and is a topical hypotensive agent frequently used for treating ocular hypertension and glaucoma. Bimatoprost also has an antiadipogenic effect[1][2].

### REFERENCES

- [1]. Park J, et al. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. *Jpn J Ophthalmol.* 2011 Jan;55(1):22-7.
- [2]. Krauss AH, et al. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. *Surv Ophthalmol.* 2004 Mar;49 Suppl 1:S5-11.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA